2,4-Dimethoxybenzoyl chloride → HCID 69064417, Verbindung
Reaktionsgleichung
[Br:1][C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]1[CH:12]=[CH:13][CH:14]=[C:7]1[CH:6]([CH2:15][CH3:16])[NH:5]2.[CH3:17][O:18][C:19]1[CH:27]=[C:26]([O:28][CH3:29])[CH:25]=[CH:24][C:20]=1[C:21](Cl)=[O:22]>>[Br:1][C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]1[CH:12]=[CH:13][CH:14]=[C:7]1[CH:6]([CH2:15][CH3:16])[N:5]2[C:21](=[O:22])[C:20]1[CH:24]=[CH:25][C:26]([O:28][CH3:29])=[CH:27][C:19]=1[O:18][CH3:17]Komponenten
3
Versuchsvorschrift
7-Bromo-5-(2,4-dimethoxybenzoyl)-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline was prepared from 7-bromo-4-ethyl-4,5-dihydropyrrolo[1,2-a]quinoxaline (see Example 42) and 2,4-dimethoxybenzoyl chloride according to the procedure of Example 106, Step 2. The product was purified via Biotage Horizon® (25S, silica gradient from 5% EtOAc/Hexane to 40% EtOAc/hexane) and isolated as a white foam. MS (ESI) m/z 441/443 ([M+H]+); HRMS: calcd for C22H21BrN2O3, 440.0736; found (ESI+), 441.08006.
Aufarbeitung
- customThe product was purified via Biotage Horizon® (25S, silica gradient from 5% EtOAc/Hexane to 40% EtOAc/hexane)
- customisolated as a white foam